Evidence map›Paper›PMID 36902277›Full record

ArticleInternational journal of molecular sciences2023

Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant.

Licia Bordi, Giuseppe Sberna, Eleonora Lalle, Lavinia Fabeni, Valentina Mazzotta, Simone Lanini, Angela Corpolongo, Anna Rosa Garbuglia, Emanuele Nicastri, Enrico Girardi and 3 more

Full text read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Licia BordiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Giuseppe SbernaLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0003-0955-2074
Eleonora LalleLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Lavinia FabeniLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Valentina MazzottaClinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0002-0240-7504
Simone LaniniClinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0002-6743-4001
Angela CorpolongoClinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0001-6235-3934
Anna Rosa GarbugliaLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Emanuele NicastriClinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0002-5606-8712
Enrico GirardiScientific Direction, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8182-5896
Francesco VaiaGeneral and Health Management Direction, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.
Andrea AntinoriClinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.ORCID 0000-0003-2121-4684
Fabrizio MaggiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, 00149 Rome, Italy.

Funding

European Commission CoNVat, Grant agreement ID 101003544; KRONO, Grant agreement ID 101005075; Grant Number SHARP: 848096Ministero della Salute Programme CCM 2020 Ricerca Corrente - Linea 1 on emerging and re-emerging infections
6 · The paper itself

Abstract

To compare the detection of the SARS-CoV-2 Omicron variant in nasopharyngeal-swab (NPS) and oral saliva samples. 255 samples were obtained from 85 Omicron-infected patients. SARS-CoV-2 load was measured in the NPS and saliva samples by using Simplexa™ COVID-19 direct and Alinity m SARS-CoV-2 AMP assays. Results obtained with the two diagnostic platforms showed very good inter-assay concordance (91.4 and 82.4% for saliva and NPS samples, respectively) and a significant correlation among cycle threshold (Ct) values. Both platforms revealed a highly significant correlation among Ct obtained in the two matrices. Although the median Ct value was lower in NPS than in saliva samples, the Ct drop was comparable in size for both types of samples after 7 days of antiviral treatment of the Omicron-infected patients. Our result demonstrates that the detection of the SARS-CoV-2 Omicron variant is not influenced by the type of sample used for PCR analysis, and that saliva can be used as an alternative specimen for detection and follow-up of Omicron-infected patients.

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesCOVID-19 TestingHumansNasopharynxSalivaSpecimen Handlingantiviral agentsCOVID-19 diagnosismonoclonal antibodiessaliva samplesSARS-CoV-2

Identifiers

PMID36902277
PMCPMC10003189

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read29
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.